HLA-C and cancer: Further, the use of these validated TCR in bispecific “immune-mobilizing-monoclonal-TCR-against-cancer” (ImmTac) formats, whereby the TCR is coupled to a stimulatory a-CD3 antibody to bind and activate any local T cells to cognate p:MHC expressing targets are also in development [146].